Re: Florus C. de Jong, Iris G. Iflé, Angelique C. van der Made, et al. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy. Eur Urol Open Sci 2024;62:131-9.
作者信息
Song Chao, Bao Jun, Wan Yu, Tang Jiyu
机构信息
State Key Laboratory of Digital Medical Engineering, Southeast University, Nanjing, China.
School of Biological Science & Medical Engineering, Southeast University, Nanjing, China.
出版信息
Eur Urol Open Sci. 2024 Jun 21;66:10-11. doi: 10.1016/j.euros.2024.04.003. eCollection 2024 Aug.
Abstract
摘要
相似文献
1
Re: Florus C. de Jong, Iris G. Iflé, Angelique C. van der Made, et al. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy. Eur Urol Open Sci 2024;62:131-9.
Eur Urol Open Sci. 2024 Jun 21;66:10-11. doi: 10.1016/j.euros.2024.04.003. eCollection 2024 Aug.
2
Reply to Chao Song's Letter to the Editor re: Florus C. de Jong, Iris G. Iflé, Angelique C. van der Made, et al. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy. Eur Urol Open Sci 2024;62:131-9.
Eur Urol Open Sci. 2024 Jun 19;66:9. doi: 10.1016/j.euros.2024.06.003. eCollection 2024 Aug.
3
Re: A Urine Based Genomic Assay to Triage Patients with Hematuria for CystoscopyK. E. M. van Kessel, J. J. de Jong, A. C. J. Ziel-van der Made, H. Roshani, S. M. Haensel, J. H. Wolterbeek, E. R. Boevé, E. H. G. M. Oomens, N. J. van Casteren, M. Krispin, J. L. Boormans, E. W. Steyerberg, W. van Criekinge and E. C. Zwarthoff 2020; 50-57.
J Urol. 2020 Nov;204(5):1062. doi: 10.1097/JU.0000000000001235. Epub 2020 Jul 6.
4
Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
Eur Urol. 2015 Aug;68(2):e31-2. doi: 10.1016/j.eururo.2015.02.044. Epub 2015 Mar 12.
5
Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
Eur Urol. 2015 Aug;68(2):e33-4. doi: 10.1016/j.eururo.2015.02.043. Epub 2015 Mar 13.
6
Re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378-84.
Eur Urol. 2012 Apr;61(4):e31-2; author reply e33-4. doi: 10.1016/j.eururo.2012.01.005. Epub 2012 Jan 11.
7
Re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A New and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378-84.
Eur Urol. 2012 Jun;61(6):e53-4; author reply e55-6. doi: 10.1016/j.eururo.2012.03.016. Epub 2012 Mar 21.
8
Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol 2019;75:853-60.
Eur Urol. 2019 Jun;75(6):e175-e176. doi: 10.1016/j.eururo.2019.02.016. Epub 2019 Feb 23.
9
Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. 2019; 75,5: 853-860.
Eur Urol. 2019 Oct;76(4):e111-e112. doi: 10.1016/j.eururo.2019.05.003. Epub 2019 May 10.
10
Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
Eur Urol. 2021 Feb;79(2):e54-e55. doi: 10.1016/j.eururo.2020.11.019. Epub 2020 Nov 26.
本文引用的文献
1
A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.
Eur Urol Open Sci. 2024 Mar 10;62:131-139. doi: 10.1016/j.euros.2024.02.009. eCollection 2024 Apr.
2
Bladder cancer.
Nat Rev Dis Primers. 2023 Oct 26;9(1):58. doi: 10.1038/s41572-023-00468-9.
3
Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer.
Clin Cancer Res. 2023 Apr 14;29(8):1582-1591. doi: 10.1158/1078-0432.CCR-22-3250.
4
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16.
5
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.
J Clin Oncol. 2019 Jun 20;37(18):1547-1557. doi: 10.1200/JCO.18.02052. Epub 2019 May 6.
Zotero 插件